Dish of the day

Joiners: 

No joiners today.

 

Leavers: 

Hyve Group (HYVE) has left the Premium Segment of the London Stock Exchange.

 

What’s cooking in the IPO kitchen?** 

The Kitchen is empty. 

 

Banquet Buffet*** 

Baron Oil 0.1p  £19m (BOIL.L) 

The oil and gas exploration company, announces its audited financial results for the year ended 31 December 2022. The net result for the year was an increased loss before taxation of £1.387m (2021: £1.127m loss). Turnover for the year was £nil (2021: £nil), there being no sales activity during the period. At the end of the financial year, cash reserves of the Group had increased to £5.807m (31 December 2021: £1.650m), following two funding events in 2022. During the year, both the Chuditch PSC and Dunrobin projects, were subject to intensive technical work aimed at maturing the assets to "drill ready" status. In early 2023 two Competent Person's Reports were published which validate both projects to the industry standard SPE PRMS Contingent and/or Prospective Resource estimates. 

 

Calnex Solutions 107p  £93.7m (CLX.L) 

The Company that provides test and measurement solutions for the global telecommunications sector announces its audited results for the 12 months ended 31 March 2023 (FY23). Revenue increased 25% to £27.4m (FY22: £22m) and profit before tax increased by 21% to £7.2m (FY22: £6.0m). CLX closed the year with a cash (including short term investments) of £19.1m (FY22: £15.4m). Whilst customer budgets continue to be restricted in the near term, customer engagement levels remain high and Calnex's mid-term order funnel has strengthened during Q1 FY24, although the timing of conversion of these opportunities into orders remains unclear. Trading in Q1 FY24 has continued as anticipated, and the Board is confident in delivering results for the year in line with market expectations as revised in March 2023. 

 

Empresaria Group 51.5p  £25.6m (EMR.L) 

The specialist staffing group provides a trading update ahead of its AGM today at 1:00pm. The softening of demand and slowing of hiring decisions seen across the Group's businesses in the second half of 2022 have continued into 2023.  As a result, net fee income for the four months to 30 April 2023 is 5% lower than the same period in the prior year and half year profits are expected to be down significantly year-on-year against a strong 2022 comparator. At present, full year adjusted profit before tax is expected to be approximately £7m. 

 

IXICO 16.75p  £8.1m (IXI.L) 

The medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2023. Revenue decreased 18% to £3.2m (H1 2022: £3.9m) and gross margin fell 46.1% (H1 2022: 59.8%). The Company reports an EBITDA loss of £0.6m (H1 2022: £0.5m profit) and £5m cash at 31 March 2023 (H1 2022: £5.8m). At the end of the period, the orderbook totalled £13.3m (H1 2022: £12.6m) following the signing of contracts totalling £11.6m across the last 12 months. Management remain confident IXICO will achieve the full year guidance of £7.0m revenues for the year. 

 

LungLife AI 49p  £12.5m (LLAI.L) 

The developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal validation study of LungLB®. Since February 2022, 425 study participants have been enrolled from seventeen sites across the United States from leading academic medical centres and Veterans Affairs hospitals. The Company is now focused on preparing the data for detailed analysis. including working with each clinical site to finalise monitoring of study data before it is unblinded. In line with expectations, the Company estimates this process will take between 3-4 months, at which point the study results are expected to be known. Following this, the Company will seek to publish the study findings in a peer-reviewed medical journal. 

 

Physiomics* 2.25p  £2.2m (PYC.L) 

The oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, provides a trading update. Due to unforeseen delays in data delivery to Physiomics for contracted projects and the signing of a project with a potential new client, the Company’s total income for the FY ending 30 June 2023 is likely to be more than 10% lower than the £750k stated in its previous guidance announced on 4 April 2023.  The Board now expects that total income for this period will be approximately £660k. The delayed contracted projects are expected to be completed in the next FY ending 30 June 2024.  The Board also expect the potential new client project to be signed this calendar year, although this cannot be guaranteed. 

 

Trellus Health 6.5p  £10.5m (TRLS.L) 

The Company which is commercialising a scientifically validated, personalised resilience-based condition management solution for chronic health conditions at their intersection with mental health, announces its audited final results for the year ended 31 December 2022. The Company generated revenue in the second half of the year, through paid sponsorship and self-paying members that are early adopters of the platform. An adjusted EBITDA loss of $8.1m was reported, in line with expectations (FY 2021: $5.7m loss). During the period, Trellus adopted a new coaching-based condition management model, facilitating rapid rollout of the Trellus ElevateTM Program across the US and Canada. In July, launched Direct-to-Consumer model, with partnerships secured with patient advocacy and groups and GI platforms to provide widespread reach to GI (gastrointestinal) patients. At the end of the period, Trellus reported net cash of $19.08m (31 December 2021: $32.0m. 

 

UK Oil & Gas 0.063p  £13.2m (UKOG.L) 

The oil and gas exploration company announces that UKOG and Aladdin Middle East, the Pinarova-1 operator, have jointly decided to temporarily suspend testing operations pending access to larger, more powerful, 7-inch perforating guns, capable of fully penetrating Pinarova's 9⅝-inch casing and cement. The decision results from analysis of downhole pressure gauge data from testing operations, which indicates that the 4.5-inch perforating guns used have been unable to establish direct contact with the formation through the casing and cement. Consequently, to date, tests have not yet been able to assess the potential of the zones associated with the 12 hours of strong crude oil odour and oil at surface as previously reported on May 3rd, 2023. A further update will follow when the date of testing operation resumption becomes clear. 

 

Ura Holdings 2.4p  £3.5m (URAH.L) 

The African-focused mineral exploration company announces it has raised £280k (before expenses) through a placing and subscription, at an issue price of 2p, representing a 10% discount to the mid-market closing price on 19 May 2023. In addition, the Company has also raised £50k by way of a convertible loan note with Austin Acquisitions 1 Limited that will convert automatically following the next annual general meeting. The proceeds of the Fundraise will be used to place orders for critical equipment required for the restart of mining operations at the Gravelotte Emerald Mine and for general working capital. 

 

XP Factory 21.5p  £32.4m (XPF.L) 

The experimental entertainment leisure business announces its audited final results for the year ended 31 December 2022. Group revenue increased 228% to £22.9m (2021: £6.9m) and gross margin rose 188% to £14.7m from £5.1m in 2021. The Group recorded its first pre-IFRS16 Adjusted EBITDA profit of £2.7m for the year (2021 of £0.6m). After IFRS 16, the Adjusted EBITDA profit was £4.1m. The Group had £3.2m of cash as at 31 December 2022, down from £8.2m at 31 December 2021.  The reduction in cash is as a result of the significant capital investment in new sites during the year. Throughout the period XP Factory successfully integrated Boom Battle Bar into the group and secured £3.3m credit facility with fit-out providers for new Boom owner operated sites. Trading in the first quarter of 2023 is currently exceeding management expectations. 

 

* A corporate client of Hybridan LLP

** Arranged by most recent first

*** Alphabetically arranged

 

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.